(IN BRIEF) A landmark international study has provided robust evidence that elevated levels of prolactin, a hormone involved in breast development, increase the risk of breast cancer in post-menopausal women. Researchers from The Institute of Cancer Research in London, along … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged B2Risk consortium, BMI, breast cancer, Breast Cancer Now, cohort studies, Dr Simon Vincent, early diagnosis, ICR, Institute of Cancer Research, invasive breast cancer, mammographic density, personalized prevention, plasma levels, PMH, polygenic risk score, post-menopausal, Professor Montse Garcia-Closas, prolactin, risk factor, targeted interventions
(IN BRIEF) Scientists at the Institute of Cancer Research in London have developed an innovative algorithm named SYLVER, which analyzes data from over 9,300 patients to identify synthetic lethal gene pairs that cancer cells depend on for survival. Unlike previous … Read the full press release
Posted in Business, Education, Financial, Healthcare, Industrial, Investment, Management, News, Science, Technology, United Kingdom
Tagged 300 patients, 9, algorithm, backup genes, BRCA mutations, Breast Cancer Now, buffering mechanism, Cancer, Cancer Genome Atlas, Cancer Research UK, Dr Hattie Brooks, Dr Simon Vincent, Dr Syed Haider, inhibitor drugs, Institute of Cancer Research, London, NIHR Biomedical Research Centre, Professor Chris Lord, protein targets, Royal Marsden NHS Foundation Trust, SYLVER, synthetic lethality, targeted therapies, tumour-suppressor genes, Walk the Walk
(IN BRIEF) Researchers have made a significant breakthrough in cancer drug discovery by identifying a new binding site on the eukaryotic initiation factor 4E (eIF4E), a protein long considered undruggable. The collaborative study between The Institute of Cancer Research (ICR) … Read the full press release
Posted in Healthcare, Pharma & Biotech, Science, Technology, United Kingdom
Tagged anticancer therapies, Astex Pharmaceuticals, breast cancer, Cancer Drug Discovery, Cancer Research UK, cancer treatment, Centre for Cancer Drug Discovery, drug development, druggable binding sites, eIF4E, eIF4G, fragment-based screening, ICR, Institute of Cancer Research, Nature Communications, new drug targets, Olivia Rossanese, Paul Clarke, prostate cancer, protein degradation, protein synthesis, protein synthesis regulation, small molecule inhibitors, therapeutic innovation, undruggable protein
(PRESS RELEASE) BRISTOL, 19-Apr-2022 — /EuropaWire/ — University of Bristol, a red brick research university, has announced that it is joining UK’s new National Mouse Genetics Network, a distributed challenge-led research clusters working with the Mary Lyon Centre to accelerate … Read the full press release
Posted in Education, Healthcare, Investment, News, Pharma & Biotech, Science, Technology, United Kingdom
Tagged biomedical sciences, brain activity, brain development, Cancer, Cardiff University, Congenital Anomalies, CRUK Beatson Institute, Degron Tagging, disease modelling, Dr Andrew Wood, Dr David Kent, Dr Michael Ashby, Dr Robert Pitceathly, Haem, Institute of Cancer Research, King’s College London, Mary Lyon Centre, microbiome, Mitochondria, mouse genetics, MRC, MRC Harwell, MRC Human Genetics Unit, MRC National Mouse Genetics Network, MURIDAE, neurodevelopmental, neuropsychiatric disease, Owen Sansom, Prof Anthony Isles, Prof Fiona Powrie, Prof Karen Blyth, Prof Karen Liu, Prof Louis Chesler, psychiatric disorders, UCL Queen Square Institute of Neurology, University of Bristol, University of Edinburgh, University of Glasgow, University of Oxford, University of York
EuropaWire (EW) is the first truly pan-European and leading press release distribution and newswire service for Europe and the European Union working towards consolidating Europe’s voice on the global newswire and media scene. The newswire service comes with advanced submission forms, flexible pricing and PR budgeting, granular targeting, nearly uncapped reach across countries, markets, verticals, industries, audiences, languages, etc., translation and localisation for greater local PR impact, in-depth distribution reporting, metrics and insights including measured PR reach, reads, engagements, impact, etc., no cap on words, images and multimedia to go along with your release, among others. Your press releases will be seen among the releases of Europe’s biggest and most prominent companies, brands and institutions.
HOW TO GET STARTED?